JP2014524480A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014524480A5 JP2014524480A5 JP2014527329A JP2014527329A JP2014524480A5 JP 2014524480 A5 JP2014524480 A5 JP 2014524480A5 JP 2014527329 A JP2014527329 A JP 2014527329A JP 2014527329 A JP2014527329 A JP 2014527329A JP 2014524480 A5 JP2014524480 A5 JP 2014524480A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical formulation
- active agent
- formulation
- pharmaceutical
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161526940P | 2011-08-24 | 2011-08-24 | |
| US61/526,940 | 2011-08-24 | ||
| US201161551506P | 2011-10-26 | 2011-10-26 | |
| US61/551,506 | 2011-10-26 | ||
| PCT/US2012/052304 WO2013028989A1 (en) | 2011-08-24 | 2012-08-24 | Formulations of active agents for sustained release |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014524480A JP2014524480A (ja) | 2014-09-22 |
| JP2014524480A5 true JP2014524480A5 (https=) | 2015-10-15 |
| JP6169079B2 JP6169079B2 (ja) | 2017-07-26 |
Family
ID=47746903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014527329A Active JP6169079B2 (ja) | 2011-08-24 | 2012-08-24 | 徐放のための活性剤の製剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20130084277A1 (https=) |
| EP (2) | EP4295858A1 (https=) |
| JP (1) | JP6169079B2 (https=) |
| CN (1) | CN104023784B (https=) |
| CA (1) | CA2846209C (https=) |
| HK (1) | HK1199418A1 (https=) |
| WO (1) | WO2013028989A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8841255B2 (en) | 2005-12-20 | 2014-09-23 | Duke University | Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides |
| US20130172274A1 (en) | 2005-12-20 | 2013-07-04 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
| EP3412300A1 (en) | 2008-06-27 | 2018-12-12 | Duke University | Therapeutic agents comprising elastin-like peptides |
| WO2012170524A1 (en) | 2011-06-06 | 2012-12-13 | Phasebio Pharmaceuticals, Inc. | Use of modified vasoactive intestinal peptides in the treatment of hypertension |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| HK1211232A1 (en) | 2012-12-21 | 2016-05-20 | Sanofi | Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists |
| TW201609799A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／ｇｉｐ受體促效劑 |
| WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| EP3080152A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Non-acylated exendin-4 peptide analogues |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| WO2015172046A1 (en) | 2014-05-08 | 2015-11-12 | Phasebio Pharmaceuticals, Inc. | Methods and compositions for treating cystic fibrosis |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| JP7075757B2 (ja) * | 2014-11-21 | 2022-05-26 | フェーズバイオ ファーマシューティカルズ，インコーポレイテッド | 制御放出および持続的放出のためのｅｌｐ融合タンパク質 |
| CA2976038A1 (en) | 2015-02-09 | 2016-08-18 | Phasebio Pharmaceuticals, Inc. | Methods and compositions for treating muscle disease and disorders |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
| ES2909074T3 (es) | 2016-05-06 | 2022-05-05 | Phasebio Pharmaceuticals Inc | Proteínas de fusión ELP para liberación controlada y sostenida |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070031342A1 (en) * | 2005-06-22 | 2007-02-08 | Nektar Therapeutics | Sustained release microparticles for pulmonary delivery |
| EP3725299A1 (en) * | 2005-06-24 | 2020-10-21 | Duke University | A direct drug delivery system based on thermally responsive biopolymers |
| CN101384272B (zh) * | 2005-12-20 | 2013-05-01 | 杜克大学 | 用于递送具有增强的药理性质的活性剂的方法和组合物 |
| US8841255B2 (en) * | 2005-12-20 | 2014-09-23 | Duke University | Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides |
| US7709227B2 (en) * | 2006-01-04 | 2010-05-04 | Phasebio Pharmaceuticals, Inc. | Multimeric ELP fusion constructs |
| EP2059606A4 (en) * | 2006-09-06 | 2010-04-07 | Phasebio Pharmaceuticals Inc | PEPTIDE FUSION THERAPEUTIC COMPOSITIONS |
| BRPI0811732A2 (pt) * | 2007-06-08 | 2014-11-18 | Boehring Ingelheim Internat Gmbh | Formulação de liberação prolongada de nevirapina |
| EP2190872B1 (en) * | 2007-09-05 | 2018-03-14 | Novo Nordisk A/S | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
| EP3412300A1 (en) * | 2008-06-27 | 2018-12-12 | Duke University | Therapeutic agents comprising elastin-like peptides |
| WO2010080578A1 (en) * | 2008-12-18 | 2010-07-15 | Phasebio Pharmaceuticals, Inc. | Biologically active proteins activatable by peptidase |
| DK3311828T3 (da) * | 2009-08-14 | 2021-06-28 | Phasebio Pharmaceuticals Inc | Modificerede vasoaktive tarmpeptider |
| WO2012170524A1 (en) * | 2011-06-06 | 2012-12-13 | Phasebio Pharmaceuticals, Inc. | Use of modified vasoactive intestinal peptides in the treatment of hypertension |
-
2012
- 2012-08-24 CA CA2846209A patent/CA2846209C/en active Active
- 2012-08-24 EP EP22213287.0A patent/EP4295858A1/en active Pending
- 2012-08-24 EP EP12826427.2A patent/EP2747832A4/en not_active Withdrawn
- 2012-08-24 WO PCT/US2012/052304 patent/WO2013028989A1/en not_active Ceased
- 2012-08-24 US US13/594,383 patent/US20130084277A1/en not_active Abandoned
- 2012-08-24 JP JP2014527329A patent/JP6169079B2/ja active Active
- 2012-08-24 CN CN201280052426.0A patent/CN104023784B/zh active Active
- 2012-08-24 HK HK14113095.1A patent/HK1199418A1/xx unknown
-
2013
- 2013-12-06 US US14/099,590 patent/US20140171370A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014524480A5 (https=) | ||
| ES2992698T3 (en) | Combination of an insulin and a glp-1 agonist | |
| AU2017361539B2 (en) | Buffered formulations of exendin (9-39) | |
| US20250000933A1 (en) | Terlipressin compositions and their methods of use | |
| CA2814057C (en) | Intravenous composition comprising paracetamol and ibuprofen | |
| HRP20170056T2 (hr) | Terapija male učestalosti glatiramer acetatom | |
| JP2018528242A (ja) | 非プロトン性極性溶媒中の安定な治療用グルカゴン製剤を製造するための方法 | |
| JP2020500864A5 (https=) | ||
| JP2020510043A5 (https=) | ||
| JP2009506978A5 (https=) | ||
| WO2019050712A1 (en) | SUBLINGUAL EPINEPHRINE TABLETS | |
| JP2020510028A5 (https=) | ||
| JP2019507174A5 (https=) | ||
| JP2023020885A5 (https=) | ||
| JP2014502608A5 (https=) | ||
| JP2008505087A5 (https=) | ||
| JP2009514869A (ja) | ヒト成長ホルモンパッチ製剤 | |
| JP2016503406A5 (https=) | ||
| CN114096269A (zh) | 高浓度胰岛素制剂 | |
| Kesavadev et al. | Newer insulins on the horizon | |
| HK40120596A (en) | Terlipressin compositions and their methods of use | |
| HK40014065B (en) | Terlipressin composition for use in treating ascites | |
| HK40014065A (en) | Terlipressin composition for use in treating ascites | |
| Rubinstein | Safety Of Nanomicellar Vasoactive Intestinal Peptide In Mice-Implications For Pulmonary Arterial Hypertension |